Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.

Next Previous
Search
Trial Profile

Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Octreotide (Primary)
  • Indications Meningioma
  • Focus Therapeutic Use
  • Acronyms CEVOREM

    • Most Recent Events

    • 24 May 2023 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2021 Results of post hoc analysis assessing the correlate 3DVGR study with patient outcome, published in the Neuro-Oncology.
    • 22 Jan 2020 Results published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top